clinical practice guideline on molecular pathology testing in ovarian cancer

Title: clinical practice guideline on molecular pathology testing in ovarian cancer
Edition: Original
Classification: Standard guideline
Field: Diagnosis and Treatment
Countries and regions: China
Guidelines users: ovarian oncologist and surgeon
Evidence classification method: The evidence level grading system was developed with reference to the GRADE system combined with clinical study results. The grades are divided into category 1, 2A, 2B and 3 to quantify the evaluation of the reliability of the evidence by the editorial committee experts. category 1: based on high-level clinical research evidence, experts' opinions are highly consistent; based on low-level clinical research evidence, experts' opinions are highly consistent; category 2A: or based on high-level evidence, experts' opinions are largely consistent; category 2B: based on low-level clinical research evidence, experts' opinions are largely consistent; category 3 : Clearly divergent expert opinions regardless of the level of clinical evidence.
Development unit: 中华医学会病理学分会;中华医学会妇科肿瘤学分会;国家病理质控中心
Registration time: 2022-06-24
Registration number: IPGRP-2022CN362
Purpose of the guideline: In order to promote the development of precise diagnosis and treatment of ovarian cancer and to standardize the application of molecular pathology testing for ovarian cancer in clinical practice, Chinese society of pathology, Chinese society of gynecological oncology and National pathology quality control center based on clinical practice data at home and abroad, combined with the national conditions of China, and complied with the guidelines for the development/revision of clinical guidelines for ovarian cancer in China (2022 edition). The aim is to systematically sort out the clinical significance and methods of molecular pathology testing for ovarian cancer, summarize the best clinical testing strategies and pathways for ovarian cancer patients, and guide the clinical practice of molecular pathology testing for ovarian cancer.